Virpax Pharmaceuticals, Inc. Common Stock
VRPX
VRPX was delisted on the 3rd of April, 2025.
6 hedge funds and large institutions have $1.12M invested in Virpax Pharmaceuticals, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 4 → 6 (+2)
14% less capital invested
Capital invested by funds: $1.29M → $1.12M (-$178K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$102K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$4.3K |
| 3 |
Morgan Stanley
New York
|
+$3.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$194K |
| 2 |
SC
Saltoro Capital
Dallas,
Texas
|
-$40.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $704K | -$194K | -181 | -23% |
|
|
ZCA
2
Zeke Capital Advisors
Berwyn,
Pennsylvania
| $205K | – | – | – |
|
|
VF
3
Virtu Financial
New York
| $107K | +$102K | +95 | New |
|
|
SC
4
Saltoro Capital
Dallas,
Texas
| $80K | -$40.8K | -38 | -35% |
|
|
5
UBS Group
Zurich,
Switzerland
| $18K | +$4.3K | +4 | +33% |
|
|
6
Morgan Stanley
New York
| $3K | +$3.22K | +3 | New |
|
VRPX Hedge Fund Activity: Q2 2021 in Review
6 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q2 2021, worth a combined $1.12M — down 14% from $1.29M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new VRPX positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $102K. The largest seller was Sabby Management, cutting an estimated $194K.
- 6 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q2 2021, up from 4 in Q1 2021.
- Funds reported $1.12M of Virpax Pharmaceuticals, Inc. Common Stock stock for Q2 2021, down 14% quarter-over-quarter.
- 2 funds opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q2 2021 and 0 closed out, a net change of +2 holders.
- The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q2 2021 was Virtu Financial, an estimated $102K added.
- The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q2 2021 was Sabby Management, an estimated $194K sold.
Based on aggregated 13F filings for Q2 2021.